Proteus Digital Health seeks to commercialize what it calls a new category of therapy: digital medicines. These offerings include widely used drugs, formulated with a sensor so they communicate when they have been swallowed; a wearable patch that detects medicines and captures physiologic response; mobile applications to support patient self-care and physician decision-making; and data analytics to serve the needs of health system managers. Some digital medicines are FDA-approved and are in commercial use in the United States currently. The company argues that data from both randomized clinical trials and real-world use demonstrate that patients have significantly improved outcomes using digital medicines (for example control of blood pressure) and that these outcomes can be sustained.
Proteus has over 450 issued patents and was founded in 2001 in the SF-bay area.
*Based on Preferred Stock Price, Proteus Digital Health does not have a stock symbol since it is currently private and is yet to have an IPO.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Proteus Digital Health or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.